Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC).
However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.
Written by:
Ismail S, Meskawi M, Hansen J, Bianchi M, Tian Z, Latour M, Graefen M, Montorsi F, Trinh QD, Perrotte P, Karakiewicz PI, Sun M. Are you the author?
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Montreal Health Center, Montreal, Canada; Martini-Klinic, Prostate Cancer Center Eppendorf-Hamburg, Hamburg, Germany; Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy; Department of Pathology, University of Montreal, Montreal, Canada; Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA; Department of Urology, University of Montreal Health Center, Montreal, Canada.
Reference: Crit Rev Oncol Hematol. 2014 Apr;90(1):49-57.
doi: 10.1016/j.critrevonc.2013.12.003
PubMed Abstract
PMID: 24411587
UroToday.com Renal Cancer Section
